Article Per Year (5 Year)
p-Index From 2021 - 2026
2.461
P-Index
This Author published in this journals
All Journal Jurnal Respirologi Indonesia Majalah Patologi Indonesia Cermin Dunia Kedokteran The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy Jurnal Penyakit Dalam Indonesia Jurnal Kesehatan Cendikia Jenius Cermin Dunia Kedokteran Kesmas: Jurnal Kesehatan Masyarakat Nasional (National Public Health Journal)
Wulyo Rajabto
Department Of Internal Medicine, Hematology Oncology Division, Cipto Mangunkusumo National Hospital, Jakarta, Indonesia
Health Professions Medicine & Pharmacology Nursing Public Health Veterinary

Published : 23 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 23 Documents
Search

 1   2   3 
Short-Term Survival and Prognostic Factors in Cervical Cancer Patients Requiring Hemodialysis: A Retrospective Cohort Study Bundjali, Muhammad Trihatmowijoyo; Marbun, Maruhum Bonar Hasiholan; Rajabto, Wulyo; Rinaldi, Ikhwan; Shatri, Hamzah; Partiningrum, Dwi Lestari; Makmun, Dadang; Nugroho, Pringgodigdo; Koesnoe, Sukamto; Soewondo, Pradana
Kesmas Vol. 21, No. 1
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Cervical cancer is a common gynecological malignancy, particularly in developing countries, where it coexists with renal impairment in over one-third of patients. This disease typically presents acutely and progresses rapidly. Consequently, kidney replacement therapy, including hemodialysis (HD), is commonly required. To assess survival rates and associated factors, this retrospective cohort study analyzed the medical records of 252 cervical cancer patients who began HD across a three-month follow-up period. Kaplan–Meier analysis indicated a median short-term survival duration of 71.5 days (range: 7–90), with 1-, 2-, and 3-month survival rates of 56%, 51%, and 49%, respectively. Multivariate Cox regression identified post-HD systolic blood pressure <110 mmHg (hazard ratio [HR] 3.354; 95% confidence interval [CI]: 2.346–4.795; p-value <0.001) and interdialytic weight gain ≥5% (HR 1.685; 95% CI: 1.125–2.521; p-value <0.011) as significant predictors of decreased survival. Other variables, including age, urea, albumin, vascular access, baseline creatinine, and cancer stage, were not significantly associated with short-term survival. These findings underscore the critical role of salt and fluid management, adherence to dietary and dialysis regimens, and close monitoring of weight in improving outcomes. Interventions targeting modifiable factors may improve the survival of cervical cancer patients who require HD. Such approaches, therefore, warrant further investigation.
Ekspresi Topoisomerase II α pada Diffuse Large B Cell Lympho-ma dan Hubungannya dengan Respon Terapi Windarti, Indri; Hardjolukito, Endang SR; Ham, Maria Francisca; Atmakusuma, Tubagus Djumhana; Rajabto, Wulyo
Majalah Patologi Indonesia Vol. 22 No. 3, September 2013
Publisher : Perhimpunan Dokter Spesialis Patologi Anatomik Indonesia (PDSPA)

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

ABSTRAK Latar belakang Kemoterapi pilihan untuk Diffuse Large B Cell Lymphoma (DLBCL) adalah regimen yang mengandung doksorubisin. Doksorubisin merupakan obat kemoterapi golongan antrasiklin yang bekerja sebagai anti Topoisomerase II (Top2). Penelitian sebelumnya terhadap galur sel tumor menunjukkan bahwa ekspresi Topoisomerase II α (Top2A) yang tinggi berhubungan dengan sensitifitas terhadap antrasiklin yang tinggi pula. Tujuan penelitian ini adalah untuk mengetahui ekspresi protein Top2A pada DLBCL dan hubungannya dengan respon terapi. Metode Studi potong lintang dilakukan terhadap 38 kasus DLBCL dengan pulasan CD20 positif, yang telah mendapat kemoterapi minimal 4 siklus. Imunohistokimia dilakukan pulasan terhadap protein Top2A dengan menggunakan H-score. Hasil Ekspresi Top2A ditemukan pada 37 dari 38 kasus (97%) dengan kisaran H-score 101,5-215,0 dan median 124,1. H-score nilai Top2A dikatakan tinggi jika H-score lebih dari 124,1. Analisis statistik menunjukkan bahwa ekspresi Top2A pada DLBCL tidak berhubungan bermakna dengan respon terapi (p=0,670). Kesimpulan Ekspresi Top2A dan respon terapi tidak memiliki hubungan bermakna. Ekpresi Top2A pada DLBCL tidak dapat dijadikan prediktor respon terapi. Kata kunci: DLBCL, Doksorubisin, ekspresi Top2A, respon terapi. ABSTRACT Background Standard of chemotherapy for Diffuse Large B Cell Lymphoma (DLBCL) is a regimen containing doxorubicin. Doxorubicin is a component of anthracycline based chemotherapy that work as anti Topoisomerase II (Top2). Previous study on tumor cell lines showed that high expression of Topoisomerase II α (Top2A) was related to higher sensitivity to anthracycline as well. The aim of this study is to know the expression of Top2A and its relation to treatment response. Methods A cross-sectional study on 38 which DLBCL cases CD20 positive that have been treated with at least 4 cycles of chemotherapy. The immunohistochemical staining was performed on Top2A protein assesed using H-score. Results Expression of Top2A protein were found in 37 of 38 (97%) cases (H-score range: 101.5-215.0 and median 124.1). Value Top2A was defined as high if H-score more was higher than 124.1. Statistical analysis showed that Top2A expression in DLBCL was not significantly related to treatment response (p=0.670). Conclusion There was no significant relation between Top2A expression and treatment response. Top2A expression in DLBCL cannot be used as a predictor of treatment response. Key words: DLBCL, Doxorubicin, Top2A expression, treatment response.
Impact of Chemotherapy on Venous Thromboembolism in Cervical Cancer: Systematic Meta-Analysis Observational Studies Fitriyadi Kusuma; Kemal Akbar Suryoadji; Wulyo Rajabto; Geraldus Sigap Gung Binathara; Shuffa Chilla Mayhana; Fahrayhansyah Muhammad Faqih; Bintang Wirawan; Abdul Hafiidh Surya Putra
Jurnal Kesehatan Cendikia Jenius Vol. 3 No. 2 (2026): April 2026
Publisher : CV. CENDIKIA JENIUS INDONESIA

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70920/jenius.v3i2.373

Abstract

Objective: Cervical cancer is associated with an increased risk of venous thromboembolism (VTE), which may be further aggravated by chemotherapy. This study aimed to assess the impact of chemotherapy on VTE incidence in patients with cervical cancer. Methods: A systematic review was conducted according to PRISMA 2020 guidelines. PubMed, the Cochrane Library, and EMBASE were searched from inception to October 2024 for observational studies reporting VTE incidence in cervical cancer patients receiving chemotherapy. Studies including women with cervical cancer treated with chemotherapy and reporting VTE outcomes were eligible, while studies evaluating radiotherapy or surgery alone were excluded. Results: Three observational studies involving 2,292 patients met the inclusion criteria. Pooled analysis showed that chemotherapy significantly increased VTE risk (RR 2.83; 95% CI: 2.05–3.90; p < 0.001), with low statistical heterogeneity. The reported incidence of chemotherapy-associated VTE ranged from 10.0% to 18.7%. Conclusion: Chemotherapy is associated with a nearly threefold increased risk of VTE in cervical cancer patients. These findings support routine VTE risk stratification prior to chemotherapy and consideration of individualized thromboprophylaxis. Further prospective studies are needed to define optimal prevention strategies.
Co-Authors A. Harryanto Abdul Hafiidh Surya Putra Achmad Fauzi Kamal Achmad, Ibrahim Adityo Susilo, Adityo Andi Putra Kevinsyah Angkasa, Yohana Kusuma Ari F Syam Ari Fahrial Syam Atmakusuma, Tubagus Djumhana Bambang Setyohadi Bintang Wirawan Birry Karim Bundjali, Muhammad Trihatmowijoyo C Martin Rumende C Martin Rumende Chici - Pratiwi Chyntia Olivia Maurine Jasirwan, Chyntia Olivia Maurine Dadang Makmun Dimas Priantono, Dimas Djumhana A Djumhana Atmakusuma Djumhana Atmakusuma Djumhana Atmakusuma, Djumhana Dwi Lestari Partiningrum E. Mudjaddid A. Siswanto Deddy N.W.Achadiono Hamzah Shatri Endang SR Hardjolukito Errol Untung Hutagalung Fachriza, Ihza Fahrayhansyah Muhammad Faqih Faisal, Edward Fitriyadi Kusuma Gabriella, Stacy Geraldus Sigap Gung Binathara Ham, Maria Francisca Hardjolukito, Endang SR Harryanto, A. Heru Sundaru Heru Widyawarman, Heru HILMAN TADJOEDIN, HILMAN Ihza Fachriza Ikhwan Rinaldi Indri Windarti Ivan Onggo S Kemal Akbar Suryoadji Khie Chen Kosasih, Kartika Anastasia Kuntjoro Harimurti Kurniadi Husodo, Kurniadi Laurentius A. Pramono M Usman SM Maharani, Sausan Hana Marbun, Maruhum Bonar Hasiholan Muradi, Akhmadu Murdani Abdullah Murdani Abdullah Myranda Zahrah Putri Nababan, Saut Horas H. Nanang Sukmana Nicholas Wijayanto Nicholas Wijayanto Pandu Tridana Sakti Parlindungan Siregar Poespitasari, Vinandya Irvianita Pradana Soewondo Pringgodigdo Nugroho, Pringgodigdo Putri, Myranda Zahrah Rahmat Cahyanur Ramadan, Edwin Ti Raniah, Nida Rudi Putranto S, Ivan Onggo Sally Aman Nasution, Sally Aman Sari, Nina Kemala Shuffa Chilla Mayhana Sihwastuti, Sihwastuti Siti Setiati Siti Setiati Stacy Gabriella Sukamto Koesnoe Sumariyono Sumariyono Suzy Maria Syahidatul Wafa Syahidatul Wafa, Syahidatul Tubagus Djumhana Atmakusuma Vito Filbert Jayalie, Vito Filbert Wijayanto, Nicholas Yohana Kusuma Angkasa Zulkifli Amin